Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00228-017-2300-9 | DOI Listing |
Eur J Clin Pharmacol
October 2017
Aix-Marseille University, Marseille, France.
J Int AIDS Soc
January 2016
Molecular and Clinical Pharmacology, Royal Liverpool University Hospital, Liverpool, UK.
Introduction: Antiretroviral therapy is recommended during pregnancy for prevention of mother-to-child transmission (MTCT) of HIV. Physiological changes during pregnancy are known to affect the pharmacokinetics (PK) of protease inhibitors (PIs), leading to lower exposures in pregnant women. Here we examine the PK of DRV/r 800/100 mg once daily (OD) over the course of pregnancy and postpartum (PP).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!